Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISCUS: 3 vs 6 cycles of platinum-based chemotherapy before maintenance avelumab in advanced urothelial cancer
2024-518244-20-01Phase 2Authorised
- Sponsor
- Queen Mary University of London
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of avelumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Change in GHS/QoL scale score from baseline to completion of 6 cycles. Planned start Apr 2022; status: authorised.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-518244-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518244-20-01.